Novel marginal zone lymphoma models of resistance to the dual inhibition of PI3K and BCL2

被引：0
|
作者：
Arribas, Alberto J.
Cascione, Luciano
Cannas, Eleonora
Bellerjeau, Helen
Fuzio, Federica
Noguera, Aleix
Rinaldi, Andrea
Esteller, Manel
Zucca, Emanuele
Alimonti, Andrea
Rossi, Davide
Stathis, Anastasios
Bertoni, Francesco
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-534
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
534
引用
收藏
页数：2
相关论文
共 50 条
  • [41] DUAL PI3K δ/γ INHIBITION SUPPRESSES M2 MACROPHAGE POLARIZATION IN HODGKIN LYMPHOMA THROUGH PKM2 DOWNREGULATION
    Locatelli, S. L.
    Careddu, G.
    Serio, S.
    Consonni, F. M.
    Maeda, A.
    Viswanadha, S.
    Vakkalanka, S.
    Morello, L.
    Magagnoli, M.
    Castagna, L.
    Santoro, A.
    Allavena, P.
    Sica, A.
    Carlo-Stella, C.
    HAEMATOLOGICA, 2018, 103 : S61 - S61
  • [42] PI3K/Akt/mTOR Pathway Inhibition in Chemotherapy-Sensitive and -Resistant Models of Burkitt Lymphoma
    Bhatti, Maria
    Ippolito, Thomas
    Mavis, Cory
    Barth, Matthew J.
    BLOOD, 2015, 126 (23)
  • [43] PI3Kδ inhibition causes feedback activation of PI3Kα in the ABC subtype of diffuse large B-cell lymphoma
    Pongas, Georgios N.
    Annunziata, Christina M.
    Staudt, Louis M.
    ONCOTARGET, 2017, 8 (47) : 81794 - 81802
  • [44] Selective PI3K and dual PI3K/mTOR inhibitors enhance the efficacy of endocrine therapies in breast cancer models
    Friedman, L.
    Ross, L. B.
    Wallin, J.
    Guan, J.
    Prior, W. W.
    Wu, E.
    Nannini, M.
    Sampath, D.
    CANCER RESEARCH, 2012, 72
  • [45] Retinoprotective effect of donepezil in diabetic mice involves mitigation of excitotoxicity and activation of PI3K/mTOR/BCl2 pathway
    Zaitone, Sawsan A.
    Alshaman, Reem
    Alattar, Abdullah
    Elsherbiny, Nehal M.
    Abogresha, Noha M.
    El-Kherbetawy, Mohammed K.
    Elaskary, Abdelhakeem A.
    Hashish, Abdullah A.
    Rashed, Laila A.
    Ahmed, Eman
    LIFE SCIENCES, 2020, 262
  • [46] BTK, BCL2 or PI3K inhibitors combined with allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia
    Schetelig, J.
    van Gelder, M.
    Michallet, M.
    Dreger, P.
    Kroeger, N.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S120 - S120
  • [47] Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors
    Guidetti, Francesca
    Arribas, Alberto J.
    Sartori, Giulio
    Spriano, Filippo
    Barnabei, Laura
    Tarantelli, Chiara
    Von Roemeling, Reinhard
    Martinez, Elizabeth
    Zucca, Emanuele
    Bertoni, Francesco
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (02)
  • [48] It Takes Two to Tango: Dual Inhibition of PI3K and MAPK in Rhabdomyosarcoma
    Jahangiri, Arman
    Weiss, William A.
    CLINICAL CANCER RESEARCH, 2013, 19 (21) : 5811 - 5813
  • [49] Targeting the PI3K/mTOR Pathway in Lymphoma with PQR309 and PQR620: Single Agent Activity and Synergism with the BCL2 Inhibitor Venetoclax
    Tarantelli, Chiara
    Gaudio, Eugenio
    Hillmann, Petra
    Spriano, Filippo
    Kwee, Ivo
    Rinaldi, Andrea
    Stathis, Anastasios
    Zucca, Emanuele
    Fabbro, Doriano
    Cmiljanovic, Vladimir
    Bertoni, Francesco
    BLOOD, 2016, 128 (22)
  • [50] Dual inhibition of MEK/MAPK and PI3K/Akt in multiple myeloma
    Steinbrunn, T.
    Stuehmer, T.
    Sayehli, C.
    Chatterjee, M.
    Einsele, H.
    Bargou, R. C.
    ONKOLOGIE, 2012, 35 : 140 - 140
12345